Category: Life Stories
Beyond Hope: 90+ New Crohn’s Therapies Could Change Everything
Over 90 new Crohn’s therapies are in development, with some showing remission rates three times higher than current treatments. This unprecedented surge in research could fundamentally change what it means to live with IBD.
Beyond IBD: When Rare Complications Threaten Remission
New research reveals that rare complications like HLH can threaten IBD patients even during remission. Learn what warning signs to watch for and how to discuss these risks with your healthcare team.
When IBD Affects Your Breathing: A Hidden Risk You Should Know
New research reveals people with IBD face nearly 50% higher risk of developing interstitial lung disease. Here’s what this means for your health and how to discuss it with your medical team.
Obefazimod Shows Promise: A New Hope for Crohn’s Treatment
Abivax’s obefazimod shows promising Phase 2b results for moderate to severe Crohn’s disease, offering hope through a novel treatment mechanism. This oral medication could provide new options for patients who haven’t found success with current therapies.
Life After Colectomy: New Hope for Crohn’s Disease of the Pouch
New research shows that two biologic medications, ustekinumab and vedolizumab, offer effective treatment options for people who develop Crohn’s disease of the pouch after ulcerative colitis surgery. This gives hope to patients facing this challenging post-surgical complication.
New Hope for Crohn’s: Targeted Therapy Takes Aim at Root Cause
AstraZeneca’s experimental treatment AZD7798 takes a precision approach to Crohn’s disease, targeting specific immune cells that cause gut inflammation rather than suppressing the entire immune system. This targeted therapy could offer new hope for patients seeking effective treatment with fewer side effects.
Hope on the Horizon: New Crohn’s Trial May Change Everything for Kids
AbbVie announces a promising new clinical trial studying Upadacitinib for children and teens with moderate to severe Crohn’s disease. This research could expand treatment options for our youngest IBD warriors who have historically had fewer therapeutic choices than adults.
New Hope: Breakthrough Crohn’s Treatment Shows Promise
New Phase 3 study results show risankizumab offering hope for Crohn’s patients who haven’t responded to anti-TNF therapies. The treatment’s convenient home delivery system is also improving patient confidence and quality of life.
New Crohn’s Treatment Shows Promise for True Healing
New clinical trial results show risankizumab achieving 52% remission rates and actual tissue healing in Crohn’s patients. This breakthrough suggests we may be moving beyond symptom management toward true intestinal repair.
The Hidden Cost of Waiting: Why IBD Diagnosis Delays Matter
New research reveals that delays in IBD diagnosis lead to worse health outcomes, including increased need for surgery and complications. Understanding this connection can help current patients advocate for faster diagnosis and appropriate care.
